Biocon receives EIR with VAI status
This is based on a surveillance inspection conducted by the USFDA between September 23-27, 2024
Biocon has received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the US Food and Drug Administration (US FDA).
The company received the EIR for their API facility (Site 2), located at SEZ Plot no. 2,3,4 and 5 Bommasandra-Jigani Link Road, Bengaluru, Karnataka.
This is based on a surveillance inspection conducted by the agency between September 23-27, 2024.
- Advertisement -